Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.

doi:10.1248/bpb.30.2146

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.

Biological & pharmaceutical bulletin - 1 Nov 2007

Takekuma Yoh, Takenaka Toru, Yamazaki Koujiro, Ueno Kazuyuki, Sugawara Mitsuru

Abstract excerpt

Carvedilol, an alpha- and beta-adrenergic blocking drug, is mainly metabolized by CYP2D6, UGT1A1, UGT2B4 and UGT2B7. This drug is administered orally as a racemic mixture of R(+)- and S(-)-enantiomers. It has been reported that CYP2D6 prefers metabolizing S-carvedilol to R-carvedilol stereoselectively. On the other hand, stereoselective metabolism of carvedilol by UGTs is still unclear. Moreover, we have reported...

Topics

Carbazoles
Carvedilol
Glucuronosyltransferase
HeLa Cells
Humans
Isoenzymes
Microsomes, Liver
Molecular Structure
Mutation
Propanolamines
Recombinant Proteins
Stereoisomerism

Source

Open in PubMed

Identifiers

PMID: 17978490
DOI: 10.1248/bpb.30.2146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics